Congress - Boston, MA, United States
Recent advances in cancer immunotherapy have turned researcher's attentions to new therapeutic strategies focused on improved specificity, control of key checkpoints in immune response, the identification of new biomarkers and novel ways of combining therapies for maximum effect. The two-conference Immunotherapies Congress offers an exciting opportunity to learn how these strategies are being translated into the next generation of cancer immunotherapeutic drug products.
The first meeting, Emerging Cancer Immunotherapies and Vaccines (August 13-14), will examine new targets and strategies in this space, and explore how the lessons learned from early cancer vaccines are driving development of longer-lasting and more potent immune responses. A second conference, Immunomodulatory Therapeutic Antibodies for Cancer (August 14-15) showcases the exciting wave of checkpoint blockades such as anti-PD-1 and anti-CTLA-4 now in clinical development -- and explores considerations of trial design, drug safety and biomarker discovery that will influence their application in patients.
(Courtesy of Tumor Immunology and Cancer, via technical.sanguinebio.com)
Tuesday, August 13, 2013
Hilton Boston Back Bay, Boston, MA, United States
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
